178 related articles for article (PubMed ID: 10321426)
21. [Irbesartan--a new AT1-receptor antagonist (AT1-blocker). Angiotensin-II-receptor antagonists: perspectives of a new therapeutic principle, Wiesbaden, 6 April 1997].
Dtsch Med Wochenschr; 1997 Sep; 122(37 Suppl):1-4. PubMed ID: 9330579
[No Abstract] [Full Text] [Related]
22. Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan.
Bramlage P; Schindler C
Expert Opin Pharmacother; 2010 Mar; 11(4):521-35. PubMed ID: 20030566
[TBL] [Abstract][Full Text] [Related]
23. Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension.
Koh KK; Han SH; Chung WJ; Ahn JY; Jin DK; Kim HS; Park GS; Kang WC; Ahn TH; Shin EK
Am J Cardiol; 2004 Jun; 93(11):1432-5, A10. PubMed ID: 15165934
[TBL] [Abstract][Full Text] [Related]
24. Cardiology patient page. Angiotensin receptor blockers.
Terra SG
Circulation; 2003 Jun; 107(24):e215-6. PubMed ID: 12821593
[No Abstract] [Full Text] [Related]
25. The angiotensin II receptor antagonist losartan: a new advance in the treatment of hypertension.
Lacourcière Y
Can J Cardiol; 1995 Aug; 11 Suppl F():45F-48F. PubMed ID: 7664218
[TBL] [Abstract][Full Text] [Related]
26. A new class of antihypertensive therapy: angiotensin II receptor antagonists.
Ellis ML; Patterson JH
Pharmacotherapy; 1996; 16(5):849-60. PubMed ID: 8888079
[TBL] [Abstract][Full Text] [Related]
27. [Angiotensin receptor antagonist for therapy of patients with hypertension].
Rakugi H; Ogihara T
Nihon Rinsho; 1997 Aug; 55(8):2075-80. PubMed ID: 9284426
[TBL] [Abstract][Full Text] [Related]
28. Irbesartan for hypertension.
Med Lett Drugs Ther; 1998 Jan; 40(1019):18-9. PubMed ID: 9465857
[No Abstract] [Full Text] [Related]
29. Angiotensin receptor antagonists.
Wong W; Howes L
Aust Fam Physician; 2000 Jul; 29(7):653-5, 658. PubMed ID: 10914449
[TBL] [Abstract][Full Text] [Related]
30. Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy.
Doggrell SA
Expert Opin Pharmacother; 2002 May; 3(5):625-8. PubMed ID: 11996640
[TBL] [Abstract][Full Text] [Related]
31. [Fast-acting sartan. High blood pressure therapy without long waiting time].
MMW Fortschr Med; 2003 Jun; 145(24):55. PubMed ID: 12866306
[No Abstract] [Full Text] [Related]
32. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.
Würzner G; Gerster JC; Chiolero A; Maillard M; Fallab-Stubi CL; Brunner HR; Burnier M
J Hypertens; 2001 Oct; 19(10):1855-60. PubMed ID: 11593107
[TBL] [Abstract][Full Text] [Related]
33. Renoprotection in Type 2 diabetes: blockade of the renin-angiotensin system with angiotensin II receptor blockers.
Swift PA; MacGregor GA
J Renin Angiotensin Aldosterone Syst; 2001 Sep; 2(3):170-3. PubMed ID: 11881118
[No Abstract] [Full Text] [Related]
34. Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Schmidt B; Schieffer B
J Med Chem; 2003 Jun; 46(12):2261-70. PubMed ID: 12773029
[No Abstract] [Full Text] [Related]
35. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
Ceriello A; Motz E
N Engl J Med; 2002 Feb; 346(9):705-7. PubMed ID: 11873779
[No Abstract] [Full Text] [Related]
36. The value of irbesartan in the management of hypertension.
Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
[TBL] [Abstract][Full Text] [Related]
37. [Irbesartan: a new possibility in the treatment of hypertension].
Rapi J
Orv Hetil; 2002 May; 143(21):1187-92. PubMed ID: 12073539
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin II receptor blockers in hypertension and renal disease.
Bakris GL
Hosp Pract (1995); 1998 Apr; 33(4):19-22. PubMed ID: 9562828
[No Abstract] [Full Text] [Related]
39. Clinical overview of irbesartan: a new angiotensin II receptor antagonist.
Pouleur HG
Am J Hypertens; 1997 Dec; 10(12 Pt 2):318S-324S. PubMed ID: 9438776
[TBL] [Abstract][Full Text] [Related]
40. Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria.
Ribeiro AB; Gavras H
Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):327-33. PubMed ID: 16767299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
